A comprehensive meta-analysis by Andrew J. Gentles et al., involving around 18,000 tumor samples across 39 different cancers, highlighted FOXM1 as a critical prognostic marker indicative of poor outcomes across a broad cancer spectrum (84). The gene discussed is FOXM1; the disease is neoplasm.